Similar articles

• Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.

  Hertz R, Bishara-Shieban J, Bar-Tana J. Hertz R, et al. J Biol Chem. 1995 Jun 2;270(22):13470-5. doi: 10.1074/jbc.270.22.13470. J Biol Chem. 1995. PMID: 7768950
• Suppression of hepatocyte nuclear factor-4alpha by acyl-CoA thioesters of hypolipidemic peroxisome proliferators.

  Hertz R, Sheena V, Kalderon B, Berman I, Bar-Tana J. Hertz R, et al. Biochem Pharmacol. 2001 May 1;61(9):1057-62. doi: 10.1016/s0006-2952(01)00578-0. Biochem Pharmacol. 2001. PMID: 11301038
• Inducers of adipose conversion activate transcription promoted by a peroxisome proliferators response element in 3T3-L1 cells.

  Brandes R, Arad R, Bar-Tana J. Brandes R, et al. Biochem Pharmacol. 1995 Nov 27;50(11):1949-51. doi: 10.1016/0006-2952(95)02082-9. Biochem Pharmacol. 1995. PMID: 8615877
• Receptor-mediated mechanisms of peroxisome proliferators.

  Green S. Green S. Biochem Pharmacol. 1992 Feb 4;43(3):393-401. doi: 10.1016/0006-2952(92)90554-v. Biochem Pharmacol. 1992. PMID: 1311577 Review. No abstract available.
• Hypolipidemia induced by PPARalpha agonists: HNF-4alpha as an alternative to PPARalpha.

  Bar-Tana J. Bar-Tana J. Curr Opin Investig Drugs. 2004 Sep;5(9):941-6. Curr Opin Investig Drugs. 2004. PMID: 15503648 Review.